Willasch, Andre Manfred and Peters, Christina and Sedlacek, Petr and Dalle, Jean-Hugues and Kitra-Roussou, Vassiliki and Yesilipek, Akif and Wachowiak, Jacek and Lankester, Arjan and Prete, Arcangelo and Hamidieh, Amir Ali and Ifversen, Marianne and Buechner, Jochen and Krivan, Gergely and Hamladji, Rose-Marie and Diaz-de-Heredia, Cristina and Skorobogatova, Elena and Michel, Gerard and Locatelli, Franco and Bertaina, Alice and Veys, Paul and Dupont, Sophie and Or, Reuven and Guengoer, Tayfun and Aleinikova, Olga and Sufliarska, Sabina and Sundin, Mikael and Rascon, Jelena and Kaare, Ain and Nemet, Damir and Fagioli, Franca and Klingebiel, Thomas Erich and Styczynski, Jan and Bierings, Marc and Nagy, Kalman and Abecasis, Manuel and Afanasyev, Boris and Ansari, Marc and Vettenranta, Kim and Alseraihy, Amal and Chybicka, Alicja and Robinson, Stephen and Bertrand, Yves and Kupesiz, Alphan and Ghavamzadeh, Ardeshir and Campos, Antonio and Pichler, Herbert and Dalissier, Arnaud and Labopin, Myriam and Corbacioglu, Selim and Balduzzi, Adriana and Galimard, Jacques-Emmanuel and Bader, Peter (2020) Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. BONE MARROW TRANSPLANTATION, 55 (8). pp. 1540-1551. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2-18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective "real-world-practice" study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; BUSULFAN-CYCLOPHOSPHAMIDE; CYTOTOXIC THERAPY; CHILDREN; BLOOD; ETOPOSIDE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Mar 2021 08:02 |
| Last Modified: | 29 Mar 2021 08:02 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44922 |
Actions (login required)
 |
View Item |
